Psoriasis is a commonly diagnosed immune-mediated disease of the skin. In psoriasis, the skin grows fast and causes a build-up of red, thick white, or silvery patches. It modifies the normal cell cycle of the skin such that new cells move to the surface of the skin quickly to form patches called plaques. These plaques are commonly found on the knees, elbows, scalp, hand and feet. The condition mostly occurs among adults (18 years-35 years), but can also be seen in adolescents (12 years-18 years) and children (under 10 years). The etiology of psoriasis is unknown; however, it is believed to be an immune-mediated process and over-activity of the immune system can also cause inflammation, resulting in flaking of the skin. The disease aggravates during winters and in a dry climate. Other triggers of psoriasis are stress, smoking, consumption of alcohol, and certain medicines like antimalarial drugs, beta blockers, and antipsychotic drugs such as those prescribed for bipolar disorder. Some risk factors of psoriasis are a genetic history of psoriasis and obesity. Plaque psoriasis, guttate psoriasis, inverse psoriasis, pustular psoriasis, and erythrodermic psoriasis are the five different types of psoriasis.

PART 01: Executive summary

Highlights

PART 02: Scope of the report

Market overview

Assumptions

Top-vendor offerings

PART 03: Market research methodology

Research methodology

Economic indicators

PART 04: Introduction

Key market highlights

PART 05: Psoriasis: Condition overview

Prevalence

Economic burden of psoriasis

PART 06: Pipeline analysis

Novel mechanisms targeted by pipeline candidates

PART 07: Market landscape

Market overview

Five forces analysis

PART 08: Market segmentation by type of molecule

Global biologics market

Small molecules

PART 09: Market segmentation by mechanism of action

TNF inhibitors

PDE4 inhibitors

IL blockers

Others

PART 10: Market segmentation by severity of disease

Mild psoriasis

Moderate psoriasis

Severe psoriasis

PART 11: Market segmentation by ROA

Oral

Parenteral

PART 12: Geographical segmentation

Systemic psoriasis therapeutics market in Americas

Systemic psoriasis therapeutics market in US

Systemic psoriasis therapeutics market in EMEA

Systemic psoriasis therapeutics market in APAC

PART 13: Market drivers

Dominance of market by biologics

Increase in psoriatic patient pool due to new diagnostic

procedures

Recurrence of psoriasis

Expected approval of late-stage pipeline molecules

PART 14: Impact of drivers

PART 15: Market challenges

Physician's reluctance to prescribe biosimilars

Innovative blue LED device and magnetic therapy as

potential therapeutics substitutes

Unknown disease etiology

Use of CAM and topical drugs to treat psoriasis

PART 16: Impact of drivers and challenges

PART 17: Market trends

Advent of biologics with novel MOA and cell-based

strategies

Emergence of next-generation systemic psoriatic

therapies

Preference for combination therapies

Popularity of off-label systemic medications

PART 18: Vendor landscape

Competitive scenario

Upcoming vendors

Key news

AbbVie

Johnson & Johnson

Celgene

Amgen

Pfizer

Other prominent vendors

PART 19: Appendix

List of abbreviations

PART 20: Explore Technavio